KLRK1 and congenital rubella syndrome: all the mice treated with the NKG2D-DAP12 CAR-T cells survived longer than NKG2D-CD3ζ CAR-T. The incorporation of the DAP12 activation domain may provide a potential clinical advantage in mitigating CRS risk